Pharming Group N.V.
Research Pharming Group N.V. (PHAR) on Bullrun: market cap USD 692.92M, P/E 78.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHAR
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 692.92M
- P/E78.8
- Financial periodQ2 2026
- RevenueUSD 90.21M
- Net incomeUSD 1.64M
- Free cash flow-USD 9.74M
- Gross margin83.9%
Valuation Snapshot
latest market cap is USD 692.92M; P/E is 78.8.
Peer valuation comparison
Latest P/E is 78.76x versus a Healthcare sector median of 24.61x (220.1% above).
Latest P/E is 78.76x versus a Netherlands median of 16.56x (375.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 376.13M | USD 2.85M | USD 53.95M | 87.9% | 0.04 | USD 145.31M | USD 115.78M | USD 277.10M |
| FY2024 | USD 297.20M | -USD 11.84M | -USD 2.59M | 88.1% | -0.16 | USD 54.94M | USD 112.31M | USD 221.06M |
| FY2023 | USD 245.32M | -USD 10.55M | -USD 18.77M | 89.7% | -0.15 | USD 61.74M | USD 171.55M | USD 218.78M |
| FY2022 | USD 205.62M | USD 13.67M | USD 20.48M | 91.5% | 0.19 | USD 207.34M | USD 166.69M | USD 204.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 692.92M | 78.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.21B | 589.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 684.39M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 753.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 719.61M | 25.7 | n/a | n/a |
| 2021 | 2021-12-31 | USD 579.98M | 35.8 | n/a | n/a |
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pharming Group N.V.'s market cap?
Pharming Group N.V.'s market capitalization is USD 692.92M.
What is Pharming Group N.V.'s P/E ratio?
Pharming Group N.V.'s price-to-earnings (P/E) ratio is 78.8.
What does Pharming Group N.V. do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K?